Immune Checkpoint Inhibitors in Combinations for Hepatocellular Carcinoma
Sharanya Maanasi Kalasekar, Ignacio Garrido‐Laguna, Kimberley Jane Evason – 11 January 2021
Dual Agonist of Farnesoid X Receptor and Takeda G Protein‐Coupled Receptor 5 Inhibits Hepatitis B Virus Infection In Vitro and In Vivo
Kiyoaki Ito, Akinori Okumura, Junko S. Takeuchi, Koichi Watashi, Rieko Inoue, Taeko Yamauchi, Kazumasa Sakamoto, Yukiko Yamashita, Yusuke Iguchi, Mizuho Une, Takaji Wakita, Kazuo Umezawa, Masashi Yoneda – 11 January 2021
LiverLearning®: 2021 Webinar: Practical Approach to Coagulation Management in Cirrhosis
Coagulation disorders in patients with cirrhosis present challenging situations for clinical providers. This one hour webinar will summarize the knowledge behind coagulation disorders in patients with cirrhosis, including the mixed and thrombosis prone model, limitations in current tests of hemostasis, and the dangers of excessive transfusion.
REPLY:
John E. Eaton, Shannon P. Sheedy, Gregory J. Gores, Sudhakar K. Venkatesh – 10 January 2021
Letter to the Editor: Imaging Monitoring of Patients With Primary Sclerosing Cholangitis
iangfa Li, Xiaofei Ye, Songqing He – 10 January 2021
Cirrhosis Is Associated With High Mortality and Readmissions Over 90 Days Regardless of COVID‐19: A Multicenter Cohort
Jasmohan S. Bajaj, Guadalupe Garcia‐Tsao, Florence Wong, Scott W. Biggins, Patrick S. Kamath, Sara McGeorge, Michael Chew, Meredith Pearson, Jawaid Shaw, Anita Kalluri, Andrew Fagan, Amy Olofson, Maryam Moini, Randolph Rosa Rodriguez, K. Rajender Reddy – 10 January 2021
Combined High‐Dose Continuous Renal Replacement Therapy and Plasma Exchange in the Management of Severe Multiorgan System Dysfunction Associated With Acute Liver Failure
Hima Veeramachaneni, Ram M. Subramanian – 10 January 2021
Death at Home May Not Always Be the Best Option
Kshitij Thakur, Jessica McFarlin – 9 January 2021
Dynamic Transcriptional and Epigenetic Changes Drive Cellular Plasticity in the Liver
Allyson J. Merrell, Tao Peng, Jinyang Li, Kathryn Sun, Bin Li, Takeshi Katsuda, Markus Grompe, Kai Tan, Ben Z. Stanger – 9 January 2021
The Use of Rifaximin in Patients With Cirrhosis
Paolo Caraceni, Victor Vargas, Elsa Solà, Carlo Alessandria, Koos Wit, Jonel Trebicka, Paolo Angeli, Rajeshwar P. Mookerjee, François Durand, Elisa Pose, Aleksander Krag, Jasmohan S. Bajaj, Ulrich Beuers, Pere Ginès, for the Liverhope Consortium – 8 January 2021 – Rifaximin is an oral nonsystemic antibiotic with minimal gastrointestinal absorption and broad‐spectrum antibacterial activity covering both gram‐positive and gram‐negative organisms.